Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
MESO
MESO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MESO News
Avaí Bio Advances Cell Therapy Production Milestone
Mar 03 2026
PRnewswire
Avaí Bio Advances α-Klotho Cell Production Milestone
Mar 03 2026
Newsfilter
Mesoblast Reports 1H 2026 Financial Results with Significant Revenue Growth
Feb 27 2026
seekingalpha
Mesoblast Reports Strong H1 FY2026 Financial Results Driven by Ryoncil Launch
Feb 27 2026
Newsfilter
Ryoncil Demonstrates High Survival Rates in Acute GVHD Treatment
Feb 12 2026
Benzinga
Mesoblast Reports Ryoncil® Treatment Data for SR-aGvHD
Feb 11 2026
Newsfilter
Mesoblast Reports Strong Q2 Performance and Financing Update
Jan 29 2026
Newsfilter
Mesoblast Reports Strong Q2 Performance with Ryoncil Sales Surge
Jan 29 2026
Yahoo Finance
Mesoblast Limited Receives FDA Feedback on BLA Filing for Rexlemestrocel-L in Chronic Low Back Pain
Jan 20 2026
Benzinga
Mesoblast Receives FDA Feedback for BLA Filing of rexlemestrocel-L
Jan 19 2026
NASDAQ.COM
Mesoblast Receives FDA Feedback on BLA Filing for rexlemestrocel-L in Chronic Low Back Pain
Jan 19 2026
Globenewswire
Exelixis Reports Preliminary 2025 Revenue of $2.123 Billion, Shares Drop 4.6%
Jan 12 2026
Benzinga
Mesoblast Reports 60% YoY Growth in Ryoncil Sales to $35.1 Million
Jan 09 2026
Benzinga
Mesoblast Reports 60% Quarterly Sales Growth for Ryoncil, Shares Jump 8%
Jan 09 2026
NASDAQ.COM
Mesoblast Reports 60% Revenue Growth to $35.1 Million in Q4
Jan 09 2026
Globenewswire
Mesoblast (MESO) Chair Jane Bell Announces Retirement
Jan 02 2026
Yahoo Finance
Show More News
